| P/E (FY) | — | Sales (TTM) | SEK 12.9M |
| Earnings (TTM) | -SEK 159.8M | ROE | −67.02% |
| Net Margin | −1242.65% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Isofol Medical AB (publ) is a clinical-stage biotechnology company developing arfolitixorin, which is in a Phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.
| Market Cap | $13.8M | Trading Days | 2202 |
| 52W High | 0.99 |
| 52W Low | 0.55 |
| % Off High | −15.66% |
| YTD | 14.54% | 1Y | −11.31% |
| 3Y | 30.67% | 5Y | −91.16% |
| Since incept. (ann.) | −26.84% |
| Ann. Volatility (1Y) | 58.41% | Ann. Volatility (3Y) | 106.53% |
| Sharpe (1Y) | 0.06 | Sharpe (3Y) | 0.57 |
| Max Drawdown (1Y) | −38.40% | Max Drawdown (3Y) | −87.22% |
| Beta (3Y, vs SPY) | −0.99 |
No same-industry peers in the universe for ISOFOL.ST.
